Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease

被引:17
作者
Panizo, Nayara [1 ]
Goicoechea, Marian [1 ]
Garcia de Vinuesa, Soledad [1 ]
Arroyo, David [1 ]
Yuste, Claudia [1 ]
Rincon, Abraham [1 ]
Verdalles, Ursula [1 ]
Ruiz-Caro, Caridad [2 ]
Quiroga, Borja [1 ]
Luno, Jose [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Serv Nefrol, Madrid 28007, Spain
[2] Clin Dialctr, Madrid, Spain
来源
NEFROLOGIA | 2012年 / 32卷 / 02期
关键词
Polycystic Kidney Diseases; BLOOD-PRESSURE; RENAL-FUNCTION; HYPERTENSION; RISK; POPULATION; PREVENTION; GUIDELINES; DIAGNOSIS; SURVIVAL; CRISP;
D O I
10.3265/Nefrologia.pre2011.Dec.11177
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of this study was to analyse the factors influencing chronic kidney disease (CKD) progression in patients with autosomal dominant polycystic kidney disease (ADPKD). Material and Method: We studied 101 patients (mean age: 43 +/- 17.3 years, 43.56% male) followed during a median (interquartile range) follow-up time of 69 (35-128) months from 1997 to 2010. The primary end point was: time to a 50% decrease of estimated glomerular filtration rate (eGFR) (CKD-EPI) since the first-time visit and/or time to initiation of renal replacement therapy. The mean anual eGFR change was also analysed. Clinical and demographic data, blood pressure, concomitant medications, and analytical parameters were collected at each visit. Baseline kidney size was also recorded by ultrasound. Results: Thirty-one patients achieved the primary end point after a median (IQR) time of 102 (53-131) months. Those patients who achieved the primary end point had higher SBP and DBP (P=0.017 and P=0.001), higher LDL-cholesterol (P=0.011), higher creatinine (P=0.006), higher uricemia (P=0.041), more severe proteinuria (P=0.033) and greater kidney size (P=0.05). The mean annual eGFR change was of -3.52 +/- 7.3ml/min/1.73m(2). Forty-nine patients had a rapid decline in renal function: Group A (higher than - 3.52ml/min/1.73m(2)) and 52 patients had a lower renal disease progression: Group B (<-3.2 ml/min/1.73 m(2)). Adjusted Cox regression analysis showed that higher SBP and younger age at the first visit were independent variables for poorer renal outcome (P=0.026). Conclusions: Initial kidney function, proteinuria, renal size, hypercholesterolemia, hyperuricemia, and SBP are the factors that influence CKD progression in ADPKD. SBP and younger age at diagnosis are the only factors that maintain their independent predictive value in a multivariant analysis.
引用
收藏
页码:197 / 205
页数:9
相关论文
共 51 条
[1]   Blood Pressure Components and the Risk for End-Stage Renal Disease and Death in Chronic Kidney Disease [J].
Agarwal, Rajiv .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (04) :830-837
[2]  
Ahmed ER, 2006, SAUDI J KIDNEY DIS T, V17, P511
[3]   Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: A progress report [J].
Antiga, Luca ;
Piccinelli, Marina ;
Fasolini, Giorgio ;
Ene-Iordache, Bogdan ;
Ondei, Patrizia ;
Bruno, Simona ;
Remuzzi, Giuseppe ;
Remuzzi, Andrea .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (04) :754-760
[4]   Family History of Renal Disease Severity Predicts the Mutated Gene in ADPKD [J].
Barua, Moumita ;
Cil, Onur ;
Paterson, Andrew D. ;
Wang, Kairon ;
He, Ning ;
Dicks, Elizabeth ;
Parfrey, Patrick ;
Pei, York .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (08) :1833-1838
[5]   Unified Ultrasonographic Diagnostic Criteria for Polycystic Kidney Disease [J].
Belibi, Franck A. ;
Edelstein, Charles L. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (01) :6-8
[6]  
Bleyer AJ, 2004, NEW ENGL J MED, V350, P2622
[7]   Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension [J].
Cadnapaphornchai, Melissa A. ;
McFann, Kim ;
Strain, John D. ;
Masoumi, Amirali ;
Schrier, Robert W. .
KIDNEY INTERNATIONAL, 2008, 74 (09) :1192-1196
[8]   Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants [J].
Cadnapaphornchai, Melissa A. ;
George, Diana M. ;
Masoumi, Amirali ;
McFann, Kim ;
Strain, John D. ;
Schrier, Robert W. .
CONTEMPORARY CLINICAL TRIALS, 2011, 32 (03) :437-445
[9]   Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort [J].
Chapman, AB ;
Guay-Woodford, LM ;
Grantham, JJ ;
Torres, VE ;
Bae, KT ;
Baumgarten, DA ;
Kenney, PJ ;
King, BF ;
Glockner, JF ;
Wetzel, LH ;
Brummer, ME ;
O'Neill, WC ;
Robbin, ML ;
Bennett, WM ;
Klahr, S ;
Hirschman, GH ;
Kimmel, PL ;
Thompson, PA ;
Miller, JP .
KIDNEY INTERNATIONAL, 2003, 64 (03) :1035-1045
[10]   Approaches to testing new treatments in autosomal dominant polycystic kidney disease: Insights from the CRISP and HALT-PKD studies [J].
Chapman, Arlene B. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (04) :1197-1204